A Peripherally Acting Nav1.7 Sodium Channel Blocker Reverses Hyperalgesia and Allodynia on Rat Models of Inflammatory and Neuropathic Pain
Authors:
- Scott B. HoytSHScott B. Hoyt
- Xiaohua LiXLXiaohua Li
- Kathryn A. LyonsKLKathryn A. Lyons
- Catherine AbbadieCACatherine Abbadie
- 1 September 2009
- journal article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 109 (3) , 951-958
Abstract
Voltage-gated sodium channels (Na(v)1) are expressed in primary sensory neurons where they influence excitability via their role in the generation and propagation of action potentials. Recently, human genetic data have shown that one sodium channel subtype, Na(v)1.7, plays a major role in pain. We performed these studies to characterize the antinociceptive effects of N-[(R)-1-((R)-7-chloro-1-isopropyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-2-(2-fluorophenyl)-ethyl]-4-fluoro-2-trifluoromethyl-benzamide (BZP), a non-central nervous system (CNS) penetrant small molecule with high affinity and preferential selectivity for Na(v)1.7 over Na(v)1.8 and Na(v)1.5. BZP was evaluated in rat preclinical models of inflammatory and neuropathic pain and compared with standard analgesics. Two models were used: the complete Freund's adjuvant model of inflammatory pain and the spinal nerve ligation model of neuropathic pain. BZP was also evaluated in a motor coordination assay to assess its propensity for CNS side effects. In preclinical models of chronic pain, BZP displayed efficacy comparable with that of leading analgesics. In the complete Freund's adjuvant model, BZP produced reversal of hyperalgesia comparable with nonsteroidal antiinflammatory drugs, and in the spinal nerve ligation model, BZP produced reversal of allodynia comparable with gabapentin and mexiletine. Unlike the CNS penetrant compounds gabapentin and mexiletine, BZP did not induce any impairment of motor coordination. These data suggest that a peripherally acting sodium channel blocker, preferentially acting through Na(v)1.7, could provide clinical relief of chronic pain without the CNS side effects typical of many existing pain treatments.Keywords
This publication has 44 references indexed in Scilit:
- Na+ channel blockers for the treatment of pain: Context is everything, almostExperimental Neurology, 2007
- Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disordersJournal of Clinical Investigation, 2007
- A stop codon mutation in SCN9A causes lack of pain sensationHuman Molecular Genetics, 2007
- A-803467, a potent and selective Na v 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the ratProceedings of the National Academy of Sciences, 2007
- What's in a name--familial rectal pain syndrome becomes paroxysmal extreme pain disorderJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain statesPain, 2006
- SCN9A Mutations Define Primary Erythermalgia as a Neuropathic Disorder of Voltage Gated Sodium ChannelsJournal of Investigative Dermatology, 2005
- Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory painPain, 2004
- Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic NeuralgiaDrugs, 2004
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983